

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 756 489 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
18.08.1999 Bulletin 1999/33

(21) Application number: 95920275.5

(22) Date of filing: 19.05.1995

(51) Int. Cl.⁶: **A61K 38/13**

(86) International application number:
PCT/KR95/00059

(87) International publication number:
WO 95/32726 (07.12.1995 Gazette 1995/52)

(54) CYCLOSPORIN CONTAINING COMPOSITION AND PROCESS FOR THE PREPARATION THEREOF

EINE CYCLOSPORIN ENTHALTENDE ZUBEREITUNG UND EIN VERFAHREN FÜR IHRE HERSTELLUNG

COMPOSITION A BASE DE CYCLOSPORINE ET SON PROCEDE DE PREPARATION

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GRIE IT LI LU MC NL
PT SE

(30) Priority: 01.06.1994 KR 1228894

(43) Date of publication of application:
05.02.1997 Bulletin 1997/06

(73) Proprietor: Yuhan Corporation
Seoul 156-020 (KR)

(72) Inventors:
• KIM, Hyun Soo
Kwacheon-si Kyonggi-do 427-010 (KR)
• CHOI, Jae Yoon
Ahnyang-si Kyonggi-do 430-080 (KR)
• LEE, Hye Weon
Ahnyang-si Kyonggi-do 430-085 (KR)

• PARK, Young Keun
Ahnyang-si Kyonggi-do 430-075 (KR)
• CHOI, Sung Wook
Seoul 156-092 (KR)

(74) Representative:
von Samson-Himmelstjerna, Friedrich R., Dipl.-
Phys. et al
SAMSON & PARTNER
Widenmayerstrasse 5
80538 München (DE)

(56) References cited:
EP-A- 0 335 627

Remarks:

The file contains technical information submitted
after the application was filed and not included in
this specification

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).


Description

Field of the Invention

5 [0001] The present invention relates to a composition comprising a cyclosporin, and to a process for the preparation thereof.

Description of the prior Art

10 [0002] Cyclosporins, a group of cyclic polypeptides comprised of 11 amino acids having the structural formula (I), are useful as an immunosuppressive which suppresses allogenic transplant rejection which may occur in the transplantation of organs of animals including human beings.



35 Cyclosporin A: R = CH₂CH₃;
 Cyclosporin B: R = CH₃;
 Cyclosporin C: R = CH(OH)-CH₃;
 Cyclosporin D: R = CH(CH₃)₂; and
 40 Cyclosporin G: R = CH₂CH₂CH₃.

In spite of their usefulness, however, pharmaceutical formulations containing cyclosporins have seen limited applications because of their extremely low solubility in water (20-30 µg/ml).

45 [0003] U.S. Patent No. 4,388,307 describes pharmaceutical compositions containing cyclosporins (SANDIMMUN or SANDIMMUNE) in the form of a solution for injection or oral administration, or a soft capsule filled with the solution. The solution is prepared by dispersing a cyclosporin into a vegetable oil by using an ethoxylated castor oil (obtained from a reaction between natural or hydrogenated castor oil and ethylene oxide) or a transesterification product of a natural vegetable oil triglyceride and a polyalkylene polyol as an emulsifier, and ethanol as a solubilizing agent. However, the process has certain drawbacks. For example, when the oily composition is contacted with an aqueous solution in mouth or
 50 intestine, the drug component is often separated as a solid, thereby reducing its bioavailability to a level of, e.g., below 30%. Moreover, in case of a long period storage, cyclosporins tend to be crystallized as the ethanol content decreases by evaporation; and patients suffer from the unpleasant odor of the ethoxylated castor oil.

[0004] Accordingly, many attempts have been made in search for a cyclosporin containing formulation with improved stability and bioavailability. For example, Japanese Patent No. 89-38029 describes a method of dissolving a cyclosporin
 55 in an organic solvent with a surfactant and then drying the resultant; German Patent Nos. 295,765 and 295,766 offer a method of dissolving cyclosporins in ethanol with a surfactant and lyophilizing the resultant; PCT international publication No. WO 90-00389 discloses a method of solubilizing cyclosporins by using a liposome and lyophilizing the resultant; and German Patent No. 293,499 presents a method of dissolving cyclosporins in propylene glycol, suspending the

solution with a polymeric polysaccharide, and solidifying the suspension with a solid carrier.

[0005] Even though the above processes may have achieved some success in improving the stability of the formulation through minimizing the ethanol content therein, they still suffer from various deficiencies. For example, the use of surfactants having a complicated composition is not practically suitable or desirable for preparing the formulation; liposome makes the whole process complicated and the reproducibility of particle size or inclusion rate is hard to control; and the use of a polymeric polysaccharide may turn the total volume of the formulation to be too bulky for administration. Further, the prior art methods still fail to produce cyclosporin containing compositions which have a satisfactory dissolution rate in an aqueous solution.

10 Summary of the Invention

[0006] Accordingly, it is an object of the present invention to provide a cyclosporin containing composition having improved stability as well as a high dissolution rate and blood concentration of cyclosporin.

15 [0007] It is another object of the present invention to provide a process for the preparation of the inventive composition.

[0008] In accordance with one aspect of the present invention, there is provided a composition comprising 1.0 to 40 wt% of a cyclosporin A, 0.1 to 30 wt% of an emulsifier and 5 to 80 wt% of a porous dextrin, based on the total weight of the composition.

20 [0009] In accordance with another aspect of the present invention, there is provided a process for preparing a cyclosporin containing composition comprising the steps of dissolving the cyclosporin A in ethanol with an emulsifier, adding a porous dextrin thereto to form a mixture, and drying the mixture.

Brief Description of the Drawing

25 [0010]

Fig. 1 shows the blood concentration of a cyclosporin of the composition of the present invention (●) and SANDIMUN (○) in a time interval.

30 Detailed Description of the Invention

[0011] A porous dextrin, which may be advantageously used in the composition of the present invention, has a high porosity. It is soluble in water, but insoluble in ethanol. When a porous dextrin is added to an ethanolic solution containing a cyclosporin and an emulsifier, the solution is adsorbed into pores of the porous dextrin, to thereby disperse the cyclosporin and the emulsifier in the porous dextrin. In case that the mixture of the porous dextrin and the ethanolic solution containing the cyclosporin and the emulsifier is diluted with a large amount of water, it is microemulsified to form an emulsion, which applied to the case that the mixture is administered into the body having an aqueous environment. Such porous dextrin may be also added as an aqueous solution thereof to the ethanolic solution containing a cyclosporin and an emulsifier, then the mixture is microemulsified by the action of the emulsifier to form a homogeneous solution. That is, the cyclosporin containing composition of the present invention shows microemulsification which increases the spreadability of the drug and delays its crystallizing process in vivo, to thereby accelerate the dissolution of cyclosporin. Besides, the composition of the present invention can be formulated into a solid form which has an increased stability and a high dissolution rate.

45 [0012] The cyclosporin containing composition of the present invention may be prepared in accordance with the procedure described below in detail.

[0013] First, a cyclosporin A is dissolved in ethanol together with an emulsifier. As the emulsifier, various pharmaceutically acceptable surfactants, preferably, Tyloxapol, Poloxamer, Tween, Labrafil and Cremophor, may be used. The emulsifier may be employed in an amount ranging from 0.1 to 30wt%, preferably from 1 to 15 wt%, based on the total weight of the composition. The amount of the cyclosporin A may range from 1.0 to 40wt%, preferably from 8 to 15 wt%, based on the total weight of the composition. Ethanol may be used in sufficient amount to dissolve the cyclosporin A and emulsifier.

50 [0014] Then, a porous dextrin is added into the ethanolic solution containing the cyclosporin A and emulsifier, in an amount ranging from 5 to 80 wt% based on the total weight of the composition. The porous dextrin may be added in the form of an aqueous solution thereof. The concentration of cyclosporin A in the aqueous solution ranges preferably from 20 to 50%(wt/wt).

55 [0015] Then, the resultant mixture is dried to obtain a cyclosporin containing composition of the present invention, e.g., in the form of fine powder or granule. Drying may be carried out by using any conventional method, preferably spray drying or drying under a reduced pressure. For example, the composition of the present invention in the form of

a fine powder may be prepared effectively by using an aqueous solution of the porous dextrin and then removing water and ethanol by spray drying.

[0016] On the other hand, the composition of the present invention in the form of a granule may be prepared by using a porous dextrin powder, and then drying it under a reduced pressure.

[0017] The cyclosporin containing composition of the present invention may be formulated in a conventional manner, if desired, with other pharmaceutical carriers, into a tablet or a capsule. The pharmaceutically acceptable carriers may include: a disintegrator such as starches, alginic acid, microcrystalline cellulose, etc.; a binding agent such as starch paste (from 10 to 80%), gelatin solution (from 10 to 20%), methylcellulose, ethylcellulose, carboxymethylcellulose, polyethyleneglycol 4000, polyethyleneglycol 6000, polyvinyl pyrrolidone, etc.; a lubricant such as magnesium stearate, calcium stearate, stearic acid, etc; and an excipient such as lactose, sugar, sodium chloride, calcium sulfate, calcium carbonate, mannitol, sorbitol, talc, mineral oil, etc.; and other pharmaceutically acceptable colorant, flavoring agent, sweetening agent, coating material and preservatives.

[0018] As described above, the cyclosporin containing composition of the present invention, when being administered into a body, may be microemulsified; and consequently, the spreadability of the cyclosporin A increases, its crystallizing decreases in vivo, and the dissolution rate markedly increases. In addition, the composition of the present invention contains very little ethanol, and, therefore, is essentially free from the stability problem caused by ethanol evaporation. Besides, the composition of the present invention has the advantage in that it can be easily formulated into a solid form.

[0019] The composition of the present invention may preferably be administered orally. The therapeutically effective amounts of cyclosporin A to be administered are well-known, e.g., a daily dosage of from about 2mg/kg to about 14 - 17.5mg/kg.

[0020] The following Examples and Tests are intended to illustrate the present invention more specifically, without limiting the scope of the invention.

Example 1

[0021] 4g of cyclosporin A and 2g of Poloxamer 407 were dissolved in 20g of ethanol. A solution of 10g of a porous dextrin (PINEFLOW[®], Matsutani Chemical Co.(Japan), specific volume: 8.5cm³/g) in 40g of purified water was added to the ethanolic solution, and the mixture was stirred for 10 minutes. The resultant was dried by spray dryer (inlet temperature : 105°C, outlet temperature : 75°C, air spraying pressure: 3kg/cm²) to obtain the composition of the present invention in powder form. The ethanol content in the powder was measured by high pressure liquid chromatography(HPLC), and the result is shown in Table 1 below.

Examples 2 - 5

[0022] The procedure of Example 1 was repeated except that the amounts of the cyclosporin A, Poloxamer 407, ethanol, the porous dextrin and purified water were varied as shown in Table 2 to obtain the compositions of the present invention in powder formulations. Their ethanol content were measured and the results are shown in Table 1 below.

Table 1

Composition	Ex. 1	Ex. 2	Ex. 3	Ex. 4	Ex. 5
Cyclosporin A (g)	4	6	8	8	8
Poloxamer 407 (g)	2	3	4	5	6
Porous dextrin (g)	10	10	10	10	10
Ethanol (g)	20	20	20	20	20
Purified Water (g)	40	40	40	40	40
Ethanol Content after Drying (%)	8.5	5.82	0.85	1.11	1.19

Example 6

[0023] 4g of cyclosporin A and 2g of Tyloxapol and 3g of Poloxamer 407 as emulsifiers were dissolved in ethanol. 10g of porous dextrin was added to the ethanolic solution, and the resultant was formulated into granule in conventional manner. The ethanol content in the granule was measured by HPLC, and the result is shown in Table 2 below.

Example 7

[0024] The procedure of Example 6 was repeated except that the amounts of the cyclosporin A, Poloxamer 407, ethanol and the porous dextrin were varied as shown in Table 2 to obtain the composition of the present invention in granule. Its ethanol content was measured and the result is shown in Table 2 below.

Table 2

Composition	Ex. 6	Ex. 7
Cyclosporin A (g)	4	4
Tyloxapol (g)	2	-
Poloxamer 407 (g)	3	4
Porous dextrin (g)	10	10
Ethanol (g)	5	5
Ethanol Content after Drying (%)	0.01	0.03

Test 1. Dissolution Test (1)

[0025] The powders prepared in Examples 1-5 were filled into hard capsules, and then the capsules were tested under the following conditions. The results are shown in Table 3 below. As comparative samples, simple mixtures of cyclosporin A, an emulsifier and dextrin, and SANDIMMUN soft capsule were used.

Dissolution Test Condition:

[0026]

Test Solution: artificial gastric juice (Ph 1.2) 900ml
 Temperature: $37 \pm 0.5^{\circ}\text{C}$
 Method: Paddle Method

Comparative Samples :

[0027]

Comparative Sample 1:

Cyclosporin A : Poloxamer 407 : Porous dextrin = 2:1:5

Comparative Sample 2:

Cyclosporin A : Poloxamer 407 = 2:1

Comparative Sample 3:

SANDIMMUN soft capsule

Table 3

Time (min)	Concentration ($\mu\text{g/ml}$)							
	Example					Comparative Example		
1	2	3	4	5	1	2	3	
5	5.0	3.0	5.5	4.0	2.6	0.5	0.4	0.25
10	7.2	4.6	7.7	6.0	3.8	0.7	0.7	0.65
20	8.8	6.3	9.3	7.4	5.0	1.0	1.0	1.00
30	9.7	7.3	9.7	8.3	5.9	0.9	0.9	1.50
60	11.3	8.6	10.8	9.7	7.7	1.6	1.6	2.00
120	13.4	9.5	11.5	10.9	8.9	2.2	2.2	2.95

Test 2 Dissolution Test (2)

[0028] The granules prepared in Examples 6 and 7 were filled into hard capsules, and then the capsules were tested under the following conditions. The results are shown in Table 4 below. As comparative samples, simple mixtures of cyclosporin A, emulsifier and dextrin, and SANDIMMUN soft capsule were used.

Dissolution Test Condition:

[0029]

Test Solution: artificial gastric juice (pH 1.2) 900ml

Temperature: $37 \pm 0.5^\circ\text{C}$

Method: Paddle Method

Comparative Samples:

[0030]

Comparative Sample 1:

Cyclosporin A : Poloxamer 407 : Porous dextrin = 2:1:5

Comparative Sample 2:

Cyclosporin A : Poloxamer 407 : = 2:1

Comparative Sample 3:

SANDIMMUN soft capsule

Table 4

Time (min)	Concentration ($\mu\text{g/ml}$)				
	Example		Comparative Example		
6	7	1	2	3	
5	5.8	9.0	0.5	0.4	0.25
10	7.3	10.6	0.7	0.7	0.65

Table 4 (continued)

Time (min)	Concentration ($\mu\text{g/ml}$)				
	Example		Comparative Example		
6	7	1	2	3	
20	8.4	11.5	0.8	1.0	1.00
30	8.9	11.7	0.9	0.9	1.50
60	9.7	12.1	1.2	1.6	2.00
120	8.7	11.8	1.3	2.2	2.95

Test 3 Bioavailability Test

[0031] The granule prepared in Example 7 was filled into hard capsules, and then the capsules were tested. As comparative sample, SANDIMMUN soft capsules were used.

[0032] Each of the test capsules and comparative capsules was administered to Beagle Dogs (9-12kg) orally at a dose of 10mg/kg of cyclosporin A. The dogs were fasted from 16 hours before until 4 hours after the administration of the drugs except water. Blood samples were taken in each amount of 100 μl at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 and 24 hours after the administration. The blood concentration of the cyclosporin A was measured by using RIA (radioimmunoassay) kit, and the results were shown in Fig.1.

[0033] As shown in Fig. 1, the composition prepared in accordance with the present invention has a maximum blood concentration (C_{max}) which is higher than the comparative sample by about 1.5 times and an area under the curve(AUC) greater than the comparative sample by about 1.3 times.

[0034] As it is clear from the above results, the composition of the present invention has a remarkably improved dissolution rate as well as superior bioavailability.

Claims

1. A composition comprising 1.0 to 40 wt% of cyclosporin A, 0.1 to 30 wt% of an emulsifier, and 5 to 80 wt% of a porous dextrin, based on the total weight of the composition.
2. The composition of claim 1, wherein said emulsifier is Tyloxapol, Poloxamer, or a mixture thereof.
3. A process for preparing a composition containing cyclosporin A, which comprises the steps of dissolving the cyclosporin A in ethanol with an emulsifier, adding a porous dextrin thereto to form a mixture, and drying the mixture.
4. The process of claim 3, wherein said emulsifier is Tyloxapol, Poloxamer, or a mixture thereof.
5. The process of claim 3, wherein said emulsifier is added in an amount of 0.1 to 30 wt% based on the total weight of the composition.
6. The process of claim 3, wherein said porous dextrin is added in an amount of 5 to 80 wt% based on the total weight of the composition.
7. The process of claim 3, wherein said porous dextrin is added in the form of an aqueous solution thereof.
8. The process of claim 7, wherein the concentration of said porous dextrin in the aqueous solution ranges from 20 to 50%.
9. The process of claim 3, wherein said drying method is performed by spray drying or under a reduced pressure.
10. A pharmaceutical formulation comprising the composition of claim 1 and a pharmacologically acceptable carrier.
11. The formulation of claim 10, which is a hard capsule.

Patentansprüche

1. Zusammensetzung, welche 1,0 bis 40 Gew.-% Cyclosporin A, 0,1 bis 30 Gew.-% eines Emulgators und 5 bis 80 Gew.-% eines porösen Dextrins, bezogen auf das Gesamtgewicht der Zusammensetzung, umfaßt.
2. Zusammensetzung nach Anspruch 1, in welcher der Emulgator Tyloxapol, Poloxamer oder eine Mischung derselben ist.
3. Verfahren zur Herstellung einer Zusammensetzung, die Cyclosporin A enthält, umfassend die Schritte des Auflö- sens des Cyclosporins A in Ethanol mit einem Emulgator, der Zugabe eines porösen Dextrins dazu, um eine Mischung zu bilden, und des Trocknens der Mischung.
4. Verfahren nach Anspruch 3, in welchem der Emulgator Tyloxapol, Poloxamer oder eine Mischung derselben ist.
5. Verfahren nach Anspruch 3, in welchem der Emulgator in einer Menge von 0,1 bis 30 Gew.-%, bezogen auf das Gesamtgewicht der Zusammensetzung, zugesetzt wird.
6. Verfahren nach Anspruch 3, in welchem das poröse Dextrin in einer Menge von 5 bis 80 Gew.-%, bezogen auf das Gesamtgewicht der Zusammensetzung, zugesetzt wird.
7. Verfahren nach Anspruch 3, in welchem das poröse Dextrin in Form einer wäßrigen Lösung desselben zugesetzt wird.
8. Verfahren nach Anspruch 7, in welchem die Konzentration des porösen Dextrins in der wäßrigen Lösung im Bereich von 20 bis 50% liegt.
9. Verfahren nach Anspruch 3, in welchem das Trocknungsverfahren durch Sprühtrocknen oder unter verringertem Druck durchgeführt wird.
10. Pharmazeutische Formulierung, umfassend die Zusammensetzung von Anspruch 1 und einen pharmakologisch annehmbaren Träger.
11. Formulierung nach Anspruch 10, bei der es sich um eine Hartkapsel handelt.

Revendications

1. Composition comprenant de 1,0 à 40 % en poids de cyclosporine A, de 0,1 à 30 % en poids d'un émulsifiant et de 5 à 80 % en poids d'une dextrine poreuse, par rapport au poids total de la composition.
2. Composition selon la revendication 1, dans laquelle ledit émulsifiant est le Tyloxapol, le Poloxamer ou un de leurs mélanges.
3. Procédé de préparation d'une composition contenant de la cyclosporine A, qui comprend les étapes de dissolution de la cyclosporine A dans de l'éthanol avec un émulsifiant, l'addition d'une dextrine poreuse pour former un mélange, et le séchage du mélange.
4. Procédé selon la revendication 3, dans lequel ledit émulsifiant est le Tyloxapol, le Poloxamer ou un de leurs mélanges.
5. Procédé selon la revendication 3, dans lequel ledit émulsifiant est ajouté en une quantité de 0,1 à 30 % en poids par rapport au poids total de la composition.
6. Procédé selon la revendication 3, dans lequel ladite dextrine poreuse est ajoutée en une quantité de 5 à 80 % en poids par rapport au poids total de la composition.
7. Procédé selon la revendication 3, dans lequel ladite dextrine poreuse est ajoutée sous forme d'une solution aqueuse.

8. Procédé selon la revendication 7, dans lequel la concentration de ladite dextrine poreuse dans la solution aqueuse est de 20 à 50 %.
- 5 9. Procédé selon la revendication 3, dans lequel ledit procédé de séchage est mis en oeuvre par séchage par atomisation ou sous pression réduite.
10. Formulation pharmaceutique comprenant la composition de la revendication 1 et un excipient acceptable d'un point de vue pharmaceutique.
- 10 11. Formulation selon la revendication 10, qui est une gélule dure.

15

20

25

30

35

40

45

50

55

Fig. 1

